Refining nanoprobes for monitoring of inflammatory bowel disease
Acta Biomaterialia · 2024-03 · 177 · 37-49
DOI: 10.1016/j.actbio.2024.02.014 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Acta Biomaterialia, 2024-03. Verfasst von Ruchen Yao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Division of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology an…. Hauptthemen laut MEDLINE: Contrast Media, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 149 Literaturangaben. Gefördert von: Shanghai Municipal Human Resources and Social Security Bureau, Shanghai Baoshan Science and Technology Commission, Renji Hospital.
Abstract (Originalsprache)
Inflammatory bowel disease (IBD) is a gastrointestinal immune disease that requires clear diagnosis, timely treatment, and lifelong monitoring. The diagnosis and monitoring methods of IBD mainly include endoscopy, imaging examination, and laboratory examination, which are constantly developed to achieve early definite diagnosis and accurate monitoring. In recent years, with the development of nanotechnology, the diagnosis and monitoring methods of IBD have been remarkably enriched. Nanomaterials, characterized by their minuscule dimensions that can be tailored, along with their distinctive optical, magnetic, and biodistribution properties, have emerged as valuable contrast agents for imaging and targeted agents for endoscopy. Through both active and passive targeting mechanisms, nanoparticles accumulate at the site of inflammation, thereby enhancing IBD detection. This review comprehensively outlines the existing IBD detection techniques, expounds upon the utilization of nanoparticles in IBD detection and diagnosis, and offers insights into the future potential of in vitro diagnostics. STATEMENT OF SIGNIFICANCE: Due to their small size and unique physical and chemical properties, nanomaterials are widely used in the biological and medical fields. In the area of oncology and inflammatory disease, an increasing number of nanomaterials are being developed for diagnostics and drug delivery. Here, we focus on inflammatory bowel disease, an autoimmune inflammatory disease that requires early diagnosis and lifelong monitoring. Nanomaterials can be used as contrast agents to visualize areas of inflammation by actively or passively targeting them through the intestinal mucosal epithelium where gaps exist due to inflammation stimulation. In this article, we summarize the utilization of nanoparticles in inflammatory bowel disease detection and diagnosis, and offers insights into the future potential of in vitro diagnostics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Division of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, Inflammatory Bowel Disease Research…
- Key Laboratory for Advanced Materials and Joint International Research Laboratory of Precision Chemistry and Molecular Engineering, Feringa Nobel Prize Scientist Joint Research Center, Institute of Fine Chemicals, Front…
Förderung
- Shanghai Municipal Human Resources and Social Security Bureau
- Shanghai Baoshan Science and Technology Commission
- Renji Hospital
- School of Medicine, Shanghai Jiao Tong University
- National Natural Science Foundation of China
Zitieren
APA
Yao, R., Zhu, M., Guo, Z., & Shen, J. (2024). Refining nanoprobes for monitoring of inflammatory bowel disease. Acta Biomaterialia, 177, 37-49. https://doi.org/10.1016/j.actbio.2024.02.014
Vancouver
Yao R, Zhu M, Guo Z, Shen J. Refining nanoprobes for monitoring of inflammatory bowel disease. Acta Biomaterialia. 2024;177:37-49. doi:10.1016/j.actbio.2024.02.014
BibTeX
@article{Yao2024,
author = {Yao, Ruchen and Zhu, Mingming and Guo, Zhiqian and Shen, Jun},
title = {Refining nanoprobes for monitoring of inflammatory bowel disease},
journal = {Acta Biomaterialia},
year = {2024},
volume = {177},
pages = {37--49},
doi = {10.1016/j.actbio.2024.02.014}
}
EUVIMED